Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.
about
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionRole of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guidelineTriglycerides as vascular risk factors: new epidemiologic insightsThe response-to-retention hypothesis of early atherogenesisConsistency of genetic inheritance mode and heritability patterns of triglyceride vs. high density lipoprotein cholesterol ratio in two Taiwanese family samplesComplications and challenges associated with polycystic ovary syndrome: current perspectivesClustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapyImpact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?Hypothesis driven single nucleotide polymorphism search (HyDn-SNP-S).The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.Hepatic lipase as a focal point for the development and treatment of coronary artery disease.Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective.The metabolic syndromeCardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008Diabetes mellitus, but not small dense low-density lipoprotein, is predictive of cardiovascular disease: A Korean community-based prospective cohort study.Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.Dietary carbohydrates and triacylglycerol metabolism.Diabetic dyslipidaemia.Intercorrelations of lipoprotein subfractions and their covariation with lifestyle factors in healthy men.Reversal of small, dense LDL subclass phenotype by normalization of adiposity.Comparison of Postprandial Responses to a High-Fat Meal in Hypertriglyceridemic Men and Women before and after Treatment with Fenofibrate in the Genetics and Lipid Lowering Drugs and Diet Network (GOLDN) Study.Reference values assessment in a Mediterranean population for small dense low-density lipoprotein concentration isolated by an optimized precipitation methodHigh density lipoproteins and type 2 diabetes: Emerging concepts in their relationship.LDL phenotype in subjects with mild cognitive impairment and Alzheimer's disease.Association of serum 25-hydroxyvitamin D with lifestyle factors and metabolic and cardiovascular disease markers: population-based cross-sectional study (FIN-D2D)Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities.Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor.Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD.Giving triglycerides their due.Reverse cholesterol transport in diabetes mellitus.Insulin resistance and cardiovascular disease.Impact of low-density lipoprotein cholesterol on cardiovascular outcomes in people with type 2 diabetes: a meta-analysis of prospective cohort studiesSerum lipid profiles, lipid ratios and Chronic Kidney Disease in a Chinese populationTriglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype.Postprandial lipemia and coronary risk.Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles.Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.Small LDL and its clinical importance as a new CAD risk factor: a female case study.Perspectives on vascular biology and diabetes.
P2860
Q21246041-DE17A126-E38D-44D0-AEB9-CCEA569A8950Q24564203-743077C5-F844-4D15-8C06-0A62CE0E4FAFQ24608464-2A0D7F3E-8A34-4A42-9F4E-1596C36ABC1AQ24618902-337CA8B2-5F39-459B-BDAE-9F3DFF0D7591Q24629974-5E2BC553-E713-41B3-BF8D-D54A1B04C709Q24798033-8F1E768D-C305-4B63-BB5F-C4E29B7DD5C1Q26799566-C222E16E-CC66-4401-8150-68D4721B611EQ28728567-7E736024-5DEB-412B-AAAE-B3C206E69E3AQ30234825-FE2BBE68-8A73-42D2-967D-302172C21EF5Q30351902-A8891F51-C6A6-4BAE-8090-11897C9BC984Q30357715-82129FDF-C2DF-40F2-8790-8435852BBFE6Q32056551-5782AE5B-5E59-45C1-858C-D280A7C47AA7Q33306319-2CBCC2CE-C4E3-43D9-936B-85E5F4F28430Q33569142-A01648DC-B987-4412-B4C3-01684E2463ACQ33602366-BDDC5A25-C2BE-4678-8A1D-109356DDC904Q33607720-E4A4F012-3286-43DB-A3A8-EDEA1E0E547BQ33639909-FA1CE5C5-6D4E-44ED-9594-E6B2ECD17DBAQ33644545-A784407D-D29D-48D7-83B8-4BF0F7B7B74CQ33670811-1394A893-A083-40F4-B1A2-213E89C5EC71Q33701744-0DF2F3C6-173B-4D12-8233-99603EA467BCQ33721993-13800105-84CC-41CD-A67F-E30B6AE75048Q33795981-284AAD39-5961-4469-ADC0-A5989796BAC1Q33803712-0EC78687-4B2C-4A51-8AC5-BFDA741DD295Q33814212-FD299A22-688C-439B-B459-2E9DEB3B68BEQ33846928-A7F2905A-07F4-48F8-AD2D-6EFECDE4661AQ33856587-E9AB5314-3837-4492-AB33-E215192A5DC4Q33889332-CE46973C-3149-4BB7-879C-07511AD0E216Q33910296-C3AD1527-FC01-41E9-AB64-7EDAFFFC4D0BQ33940875-014C5384-A140-4BAC-ACC3-2229DBBE285AQ33972829-795499AA-41CA-4FED-88A6-B69A6FACD38DQ33996892-8E16F960-C6A7-4619-B919-C8DE35E88C25Q34011027-23DC5C69-D494-41D6-9D7F-7A529185D570Q34077856-8B2275CB-D14B-4E37-B177-D370A02B626DQ34086005-85DB0C80-A5C9-489A-93AC-DFA7A41F8FCAQ34107409-6220446F-F87C-4A72-9420-5C4E3DCA43F4Q34107425-6A98FAAA-83F6-4391-B3F1-A1BDB95260C9Q34110733-F8DB682C-9AD1-46CA-974E-D1357C353554Q34110947-26357C9A-CE75-4638-9EDC-26B6B12F5262Q34157888-189919A5-815A-4C1A-B8E8-F41FA17C61AAQ34161037-80EB89CC-8295-4F4D-9969-397FAC51D425
P2860
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Atherogenic lipoprotein phenot ...... r coronary heart disease risk.
@en
Atherogenic lipoprotein phenot ...... r coronary heart disease risk.
@nl
type
label
Atherogenic lipoprotein phenot ...... r coronary heart disease risk.
@en
Atherogenic lipoprotein phenot ...... r coronary heart disease risk.
@nl
prefLabel
Atherogenic lipoprotein phenot ...... r coronary heart disease risk.
@en
Atherogenic lipoprotein phenot ...... r coronary heart disease risk.
@nl
P2093
P356
P1433
P1476
Atherogenic lipoprotein phenot ...... or coronary heart disease risk
@en
P2093
K M Vranizan
M A Austin
R M Krauss
P304
P356
10.1161/01.CIR.82.2.495
P407
P577
1990-08-01T00:00:00Z